Volume 24, Issue 11 pp. 1111-1114
Original Article

Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis

Yuben P. Moodley

Corresponding Author

Yuben P. Moodley

School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia

Stem Cell Unit, Institute for Respiratory Health, Perth, WA, Australia

Department of Respiratory Medicine, Fiona Stanley Hospital, Perth, WA, Australia

National Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia

Correspondence: Yuben P. Moodley, School of Medicine, University of Western Australia, Level 2, Harry Perkins Institute of Medical Research, Fiona Stanley Hospital Campus, 5 Robin Warren Drive, Murdoch, Perth, WA 6150, Australia. Email: [email protected]Search for more papers by this author
Tamera J. Corte

Tamera J. Corte

National Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia

Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia

School of Medicine, University of Sydney, Sydney, NSW, Australia

Search for more papers by this author
Brian G. Oliver

Brian G. Oliver

Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia

Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia

Search for more papers by this author
Ian N. Glaspole

Ian N. Glaspole

National Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia

Department of Allergy and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia

Faculty of Medicine, Monash University, Melbourne, VIC, Australia

Search for more papers by this author
Andreja Livk

Andreja Livk

Proteomics International, Perth, WA, Australia

Search for more papers by this author
Jason Ito

Jason Ito

Proteomics International, Perth, WA, Australia

Search for more papers by this author
Kirsten Peters

Kirsten Peters

Proteomics International, Perth, WA, Australia

Search for more papers by this author
Richard Lipscombe

Richard Lipscombe

Proteomics International, Perth, WA, Australia

Search for more papers by this author
Tammy Casey

Tammy Casey

Proteomics International, Perth, WA, Australia

Search for more papers by this author
Dino B.A. Tan

Dino B.A. Tan

School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia

Stem Cell Unit, Institute for Respiratory Health, Perth, WA, Australia

Search for more papers by this author
First published: 08 August 2019
Citations: 16
(Associate Editor: Michael Keane; Senior Editor: Chris Grainge)
See relatedEditorial

ABSTRACT

Background and objective

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease that has a poor 3-year median survival rate with unclear pathophysiology. Radiological features include bibasal, subpleural fibrosis and honeycombing while its pathology is characterized by fibroblastic foci and honeycombing. Proteomic analysis of circulating molecules in plasma may identify factors that characterize IPF and may assist in the diagnosis, prognostication and determination of pathogenic pathways in this condition.

Methods

Two independent quantitative proteomic techniques were used, isobaric tags for relative and absolute quantitation (iTRAQ) and multiple reaction monitoring (MRM), to identify differentially expressed plasma proteins in a group of IPF patients in comparison to healthy controls with normal lung function matched for age and gender.

Results

Five proteins were identified to be differentially expressed in IPF compared to healthy controls (upregulation of platelet basic protein and downregulation of actin, cytoplasmic 2, antithrombin-III, extracellular matrix protein-1 and fibronectin).

Conclusion

This study further validates the combinational use of non-targeted discovery proteomics (iTRAQ) with targeted quantitation by mass spectrometry (MRM) of soluble biomarkers to identify potentially important molecules and pathways for pulmonary diseases such as IPF.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.